SpaceOAR Flex System
BOSTON SCIENTIFIC CORPORATION · Decision date Sep 11, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for K262151, the SpaceOAR Flex™ System, on September 11, 2026, with the submission received June 25, 2026. The applicant is Boston Scientific Corporation; the device falls under 21 CFR 892.5725 (absorbable perirectal spacer), Class II, product code OVB, in the Radiology specialty. SESE in a 510(k) is a clearance, not a PMA approval.
The subject device is a sterile, single-use PEG hydrogel spacer supplied as two pre-filled glass syringes with a luer connector and a separately pouched 18 G x 15 cm needle; the hydrogel is polymerized during manufacturing. The listed predicate is the SpaceOAR Vue™ System (K182971, cleared July 19, 2019), with identical indications for use and principles of operation. The summary table records differences in components, sterilization (moist heat and X-ray versus gamma) and shelf life (18 versus 24 months). The source does not state the basis for the clinical trial identifier listed on the FDA page.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Sep 11, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262151
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- BOSTON SCIENTIFIC CORPORATION
- Product code
- OVB
- Decision code
- SESE
- Decision date
- Sep 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Hydrogel Spacer.
- Applicant
- Boston Scientific Corporation
- Product code
- OVB
- FDA device class
- 2
FDA decision timeline
K262151 received
Application receipt date recorded by FDA.
K262151 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corporation
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- Marlborough, MA
Sources and methodology
- Original FDA record: K262151
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records